Volume 29, No 10, Oct 2019
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 29 Issue 10, October 2019: 783-784
RESEARCH HIGHLIGHTS
Mutagenic replication: target for tumor therapy?
Jacob G. Jansen1 and Niels de Wind 1
1 Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
Correspondence: Niels de Wind (N.de_Wind@lumc.nl)
A study published in Cell by Wojtaszek et al. provides a proof of principle that cancer cells can be sensitized to DNA-damaging chemotherapy by the drug-induced inhibition of mutagenic DNA translesion synthesis, a process that endows tolerance of DNA damage. However, the risk/benefit profile of such a combination therapy should be thoroughly evaluated.
https://doi.org/10.1038/s41422-019-0218-8
FULL TEXT | PDF
Browse 839
